Strides Arcolab today announced that Gilead Sciences has licensed the company to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment of chronic hepatitis C. This is for distribution to 91 developing countries including India, Egypt and Indonesia which are high burden countries.
Under the licensing agreements, Strides receives a complete technology transfer of the Gilead manufacturing process for both API and finished product. This will enable scale up production as quickly as possible, the company said.
